Diversion Control Division, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

December

Kerry Farms LLC (PDF) (December 1, 2022)


November

Final Rule; Correction: Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a Registration (PDF) (November 29, 2022)

Final Rule: Placement of Mesocarb in Schedule I (PDF) (November 22, 2022)

Final Rule: Removal of [18F]FP-CIT From Control (PDF) (November 21, 2022)

Final Rule: Placement of Zipeprol in Schedule I (PDF) (November 21, 2022)

Adley Dasilva, P.A.; Decision and Order (PDF) (November 18, 2022)

Berkshire Roots, Inc. (PDF) (November 18, 2022)

Vici Health Sciences, LLC (PDF) (November 18, 2022)

Final Rule: Placement of Amineptine in Schedule I (PDF) (November 17, 2022)

Final Rule: Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a Registration (PDF) (November 14, 2022)

Final Rule: Specific Listing for 1-boc-4-AP, a Currently Controlled List I Chemical (PDF) (November 9, 2022)

Final Rule: Placement of Ganaxolone in Schedule V (PDF) (November 9, 2022)

Nicky Shah, M.D.; Decision and Order (PDF) (November 8, 2022)

George M. Douglass, M.D.; Decision and Order (PDF) (November 8, 2022)

Gerald M. Baltz, N.P.; Decision and Order (PDF) (November 8, 2022)

Chattem Chemicals, Inc.; Correction (PDF) (November 8, 2022)

Final Rule: Technical Correction to Regulation Regarding Registration Exception for Officials (PDF) (November 7, 2022)

Organix Chemistry Solutions LLC (PDF) (November 4, 2022)


October

Nanosyn Inc. (PDF) (October 31, 2022)

Noramco (PDF) (October 31, 2022)

Curia New York, Inc. (PDF) (October 31, 2022)

Mylan Technologies, Inc. (PDF) (October 31, 2022)

Fisher Clinical Services, Inc. (PDF) (October 24, 2022)

Morrison Newfound Valley Manufacturing (PDF) (October 24, 2022)

Rocky Mountain Biotech, LLC (PDF) (October 24, 2022)

Nexus Pharmaceuticals, Inc. (PDF) (October 24, 2022)

Benuvia Manufacturing, Inc. (PDF) (October 24, 2022)

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023 (PDF) (October 18, 2022)

National Center for Natural Products Research (PDF) (October 18, 2022)

Organic Standards Solutions International, LLC (PDF) (October 18, 2022)

Irvine Labs, Inc. (PDF) (October 13, 2022)

Groff NA Hemplex LLC (PDF) (October 13, 2022)

National Center for Natural Products Research (PDF) (October 13, 2022)

Fisher Clinical Services, Inc. (PDF) (October 13, 2022)

Eli-ElSohly Laboratories (PDF) (October 11, 2022)

Hybrid Pharma (PDF) (October 11, 2022)

Groff NA Hemplex LLC (PDF) (October 11, 2022)

Cambrex High Point, Inc. (PDF) (October 11, 2022)

Curia Missouri, Inc. (PDF) (October 11, 2022)

Curia Wisconsin, Inc. (PDF) (October 11, 2022)

Curia New York, Inc. (PDF) (October 11, 2022)

Chattem Chemicals, Inc. (PDF) (October 11, 2022)

VICI Health Sciences, LLC (PDF) (October 11, 2022)

Cambridge Isotope Laboratories Inc. (PDF) (October 7, 2022)

Cardinal Health, DBA Specialty Pharmaceutical Service (PDF) (October 7, 2022)

Fresenius Kabi USA, LLC (PDF) (October 7, 2022)

Cambrex High Point, Inc. (PDF) (October 7, 2022)


September

Final Rule: Placement of Daridorexant in Schedule IV (PDF) (September 30, 2022)

Matt M. Ahmadi, D.P.M.; Decision and Order (PDF) (September 30, 2022)

Thomas Blair, M.D.; Decision and Order (PDF) (September 30, 2022)

Lewisville Medical Pharmacy; Decision and Order (PDF) (September 30, 2022)

Proposed Rule: Designation of 4-Piperidone as a List I Chemical (PDF) (September 22, 2022)

Rayford ACP; Decision and Order (PDF) (September 15, 2022)

Reginald James Newsome, M.D.; Decision and Order (PDF) (September 15, 2022)

Bernadette U. Iguh, M.D.; Decision and Order (PDF) (September 15, 2022)

Mohammad H. Said, M.D.; Decision and Order (PDF) (September 15, 2022)

Cayman Chemical Company (PDF) (September 8, 2022)

Catalent CTS, LLC (PDF) (September 8, 2022)

Curia Wisconsin, Inc. (PDF) (September 8, 2022)

Wedgewood Village Pharmacy, LLC (PDF) (September 1, 2022)


August

Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (August 31, 2022)

Experic LLC (PDF) (August 31, 2022)

Purisys, LLC (PDF) (August 30, 2022)

Caligor Coghlan Pharma Services (PDF) (August 30, 2022)

Withdrawal of Proposed Rule: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (August 29, 2022)

Cambridge Isotope Laboratories, Inc. (PDF) (August 12, 2022)

Galephar Pharmaceutical Research, Inc. (PDF) (August 12, 2022)

Lipomed (PDF) (August 10, 2022)

Cambrex Charles City (PDF) (August 10, 2022)

VA Cooperative Studies Program (PDF) (August 10, 2022)

Epic Pharma, LLC (PDF) (August 10, 2022)

Chemtos, LLC (PDF) (August 9, 2022)

Catalent Pharma Solutions, LLC (PDF) (August 9, 2022)

Botanical Sciences, LLC (PDF) (August 9, 2022)

Cerilliant Corporation (PDF) (August 9, 2022)

Cerilliant Corporation (PDF) (August 9, 2022)

Experic LLC (PDF) (August 9, 2022)

Sharp Clinical Services, LLC (PDF) (August 9, 2022)

VHG Labs, DBA LGC Standards (PDF) (August 9, 2022)

Stepan Company (PDF) (August 9, 2022)

Continuus Pharmaceutical (PDF) (August 9, 2022)

Biopharmaceutical Research Company (PDF) (August 9, 2022)

Curium US LLC (PDF) (August 9, 2022)

Bright Green Corporation (PDF) (August 9, 2022)

Chattem Chemicals (PDF) (August 9, 2022)

Michael Simental, M.D.; Decision and Order (PDF) (August 3, 2022)

Rebecca L. Adams, N.P.; Decision and Order (PDF) (August 3, 2022)

Endre Kovacs, M.D.; Decision and Order (PDF) (August 3, 2022)

30-Day Notice: Report of Mail Order Transactions (PDF) (August 1, 2022)

30-Day Notice: Reporting and Recordkeeping for Digital Certificates (PDF) (August 1, 2022)


July

Usona Institute (PDF) (July 29, 2022)

Biopharmaceutical Research Company LLC (PDF) (July 28, 2022)

AndersonBrecon Inc. (PDF) (July 28, 2022)

AMPAC Fine Chemicals Virginia, LLC (PDF) (July 28, 2022)

Akorn Operating Company, LLC DBA Akorn (PDF) (July 28, 2022)

Aspen API, Inc. (PDF) (July 28, 2022)

Withdrawal of Proposed Rule: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I (PDF) (July 27, 2022)

Proposed Rule: Removal of Fenfluramine From Control (PDF) (July 19, 2022)

Proposed Rule: Providing Controlled Substances to Ocean Vessels, Aircraft, and Other Entities (PDF) (July 18, 2022)

Faris Abusharif, M.D.; Decision and Order (PDF) (July 18, 2022)

Xcelience (PDF) (July 15, 2022)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (July 15, 2022)

AMPAC Fine Chemicals LLC (PDF) (July 15, 2022)

Donald J. Murphy, M.D.; Decision and Order (PDF) (July 12, 2022)

Alphonsus Okoli, M.D.; Decision and Order (PDF) (July 12, 2022)

Bhanoo Sharma, M.D.; Decision and Order (PDF) (July 12, 2022)

Proposed Rule: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I (PDF) (July 6, 2022)

Emergency Disaster Relief
Search for Year Round Pharmaceutical Disposal Locations.
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility